Davis-based cancer drug startup raises $2.7 million


CEO Lonnie Bookbinder says the startup is part of a larger effort to commercialize research coming out of the University of California Davis.

Previous Bitcoin review: Status.IM in battle mode, LinkedIn bets on blockchain
Next Burks named next CEO of UNC Health Care